In the first quarter of 2025, net revenue increased organically with continued good profitability, which shows stable demand in medical technology and laboratory solutions. Cash flow from operating activities was strong, driven by improved working capital while EBITA, the company’s new main profit measure, decreased compared to the same quarter last year. Through increased operational … Read more
The first quarter saw a continued favourable revenue development. The Lab segment delivered strong organic growth whereas our pharmaceuticals business affected the Group negatively. The changing product mix resulted in lower margins. Work continued to optimise the capital structure and profit for the period improved. January – March 2024 Net revenue for the period was … Read more
January-March 2023 Net revenue for the period was SEK 310.5 million (162.4), an increase of 91.2%. Organic growth was 19.7%. Orders received for the period was SEK 340.3 million (130.8), an increase of 160.2%. Organic growth was 86.5%. EBITDA for the period was SEK 84.2 million (21.2) Profit/loss for the period was SEK 35.6 million … Read more
January-March 2022 Net revenue for the period was SEK 162.4 million (87.7), an increase of 85.1 %. Organic growth was 4.2 %. Adjusted EBITDA for the period was SEK 21.3 million (8.0) EBITDA for the period was SEK 21.2 million (8.9) Adjusted profit/loss for the period was SEK 5.8 million (1.6) Basic earnings per share … Read more
January – March 2021 Net revenue for the period was SEK 87.7 million (83.7) EBITDA for the period was SEK 8.9 million (5.4) EBITA for the period was SEK 6.9 million (3.4) Profit/loss for the period was SEK 2.5 million (-2.5) Basic earnings per share for the period amounted to SEK 0.02 (-0.02) Orders received … Read more